Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | NT5E | P21589 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.59 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1898718 | 1.00 | LMNA (0.62) | LMNATP53CYP2C19NT5EHIF1A | |
| SCHEMBL11311292 | 0.90 | ADORA3 (0.60) | LMNATP53CYP2C19NT5EHIF1A | |
| SCHEMBL11311318 | 0.90 | ADORA3 (0.60) | LMNATP53CYP2C19NT5EHIF1A | |
| Xanthosine SCHEMBL6676995 | 0.88 | LMNA (0.65) | LMNATP53CYP2C19NT5EHIF1A | |
| Xanthosine SCHEMBL188120 | 0.88 | LMNA (0.65) | LMNATP53CYP2C19NT5EHIF1A | |
| Xanthosine SCHEMBL11523732 | 0.88 | LMNA (0.65) | LMNATP53CYP2C19NT5EHIF1A | |
| Xanthosine SCHEMBL8665102 | 0.88 | LMNA (0.65) | LMNATP53CYP2C19NT5EHIF1A | |
| SCHEMBL16619900 | 0.87 | ADORA3 (0.64) | NT5EADORA2AADORA2BADORA3ADORA1 | |
| 2-Methyladenosine SCHEMBL278664 | 0.87 | LMNA (0.75) | LMNANT5EHIF1AADORA2AADORA2B | |
| 2-Methyladenosine SCHEMBL18159462 | 0.87 | LMNA (0.75) | LMNANT5EHIF1AADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230407419-A1 | Rapid Diagnostic Test for LAMP | NEW ENGLAND BIOLABS, INC. (US) | 2023-12-21 | — | — | US | disclosed |
| US-11732315-B2 | Rapid diagnostic test for lamp | NEW ENGLAND BIOLABS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| CN-116529363-A | RNA-guided clearance of herpes simplex virus type I and other related human herpesviruses | 天普大学-联邦高等教育系统 | 2023-08-01 | — | — | CN | disclosed |
| US-20230048863-A1 | Rapid Diagnostic Test for LAMP | NEW ENGLAND BIOLABS, INC. (US) | 2023-02-16 | — | — | US | disclosed |
| US-20230022745-A1 | Methods for Labeling a Population of RNA Molecules | NEW ENGLAND BIOLABS, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| EP-4118233-A1 | A RAPID DIAGNOSTIC TEST FOR LAMP | New England Biolabs, Inc. (US) | 2023-01-18 | — | — | EP | disclosed |
| EP-4110945-A2 | A RAPID DIAGNOSTIC TEST FOR LAMP | New England Biolabs, Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| US-11525166-B2 | Rapid diagnostic test for LAMP | NEW ENGLAND BIOLABS, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-11479766-B2 | Methods for labeling a population of RNA molecules | NEW ENGLAND BIOLABS, INC. (US) | 2022-10-25 | — | — | US | disclosed |
| CN-105518146-B | Therapeutic uses of genome editing with CRISPR/Cas systems | 哈佛学院校长同事会 | 2022-07-15 | — | — | CN | disclosed |
| WO-1997033590-A1 | A METHOD OF TREATING DISORDERS RELATED TO CYTOKINES IN MAMMALS | NOVO NORDISK A/S (DK) | 1997-09-18 | — | — | WO | disclosed |
| WO-1997033591-A1 | A METHOD OF TREATING DISORDERS RELATED TO CYTOKINES IN MAMMALS | NOVO NORDISK A/S (DK) | 1997-09-18 | — | — | WO | disclosed |
| US-5484774-A | 2, N6 -disubstituted adenosines, tri-O-ester derivatives and their pharmaceutical compositions to treat ischemias | NOVO NORDISK A/S (DK) | 1996-01-16 | — | — | US | disclosed |
| EP-0675896-A1 | PURINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1995-10-11 | — | — | EP | disclosed |
| US-5430027-A | 2-chloro-N6 -substituted adenosines, their pharmaceutical compositions, and activity in treating ischemias | NOVO NORDISK A/S (DK) | 1995-07-04 | — | — | US | disclosed |
| EP-0607367-A1 | NOVEL ADENOSINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1994-07-27 | — | — | EP | disclosed |
| WO-1994014832-A1 | PURINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1994-07-07 | — | — | WO | disclosed |
| EP-0603348-A1 | PURINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1994-06-29 | — | — | EP | disclosed |
| WO-1993023417-A1 | NOVEL ADENOSINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1993-11-25 | — | — | WO | disclosed |
| WO-1993023418-A1 | PURINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11479766-B2 | Methods for labeling a population of RNA molecules | RNGTT, RNMT, MTAP | LMNA 2087/4885TP53 1802/4885CYP2C19 4739/4885 |
| US-20230022745-A1 | Methods for Labeling a Population of RNA Molecules | RNGTT, RNMT, MTAP | LMNA 2087/4885TP53 1802/4885CYP2C19 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.